Key facts
- Biosimo’s last known valuation is $9.2M (Jun 2025).
- It has raised $5.4M; the latest was Accelerator/Incubator in Sep 2025.
- Notable investors include MassChallenge, Venture Kick, Activate Global, Innosuisse, Kickfund — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Biosimo
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosimo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosimo
Developer of bio-based acetyl products designed to integrate into existing bulk industrial production processes, operating in the sustainable chemicals industry. The company offers bio-based acetyl manufacturing technologies compatible with current industrial infrastructure and supply chains, enabling chemical manufacturers to adopt renewable inputs while maintaining cost competitiveness, performance consistency, and reliable large-scale production.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2022
- Employees
- 4
- Website
- biosimo-chemicals.com/
- Ownership
- Privately Held (backing)
Biosimo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosimo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosimo in its N-PORT filings yet. We sweep new filings monthly.